{"protocolSection":{"identificationModule":{"nctId":"NCT03220737","orgStudyIdInfo":{"id":"PXVX-VC-200-006"},"organization":{"fullName":"Bavarian Nordic","class":"INDUSTRY"},"briefTitle":"VAXCHORA Pediatric Study to Assess Safety and Immunogenicity","officialTitle":"A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-07-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-09-10","type":"ACTUAL"},"completionDateStruct":{"date":"2020-03-06","type":"ACTUAL"},"studyFirstSubmitDate":"2017-07-11","studyFirstSubmitQcDate":"2017-07-13","studyFirstPostDateStruct":{"date":"2017-07-18","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-09-08","resultsFirstSubmitQcDate":"2020-10-27","resultsFirstPostDateStruct":{"date":"2020-11-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-26","lastUpdatePostDateStruct":{"date":"2023-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bavarian Nordic","class":"INDUSTRY"},"collaborators":[{"name":"Emergent BioSolutions","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1. VAXCHORA is approved for use in adults 18 through 64 years of age travelling to cholera-affected areas. The primary goals of this Phase 4 study are to evaluate the safety and immunogenicity of a single dose of VAXCHORA (1 x 10e9 cfu/dose) in children ages 2 years to \\<18 years of age in developed countries.","detailedDescription":"This is a randomized, placebo-controlled, double-blind, single-crossover study with three age cohorts and two treatment groups within each cohort."},"conditionsModule":{"conditions":["Cholera (Disorder)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","interventionModelDescription":"This is a randomized, placebo-controlled, double-blind, single-crossover study with three age cohorts and two treatment groups within each cohort.\n\nThe main study consists of a screening period of 30 days, a treatment period from Day 1 to Day 29, and a follow-up period through Day 181. Cohort 1 has an optional sub-study consisting of a long-term follow-up period through Day 730.","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"The study will be conducted as a double-blind study through 181, where neither the sponsor, the statistical team, study volunteer subjects, nor clinical site personnel (except for the unblinded administration staff) will know subjects' treatment assignment. Once each subject has reached their Day 181 visit they will be individually unblinded.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":550,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1 (active, 12-17 yrs)","type":"EXPERIMENTAL","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.","interventionNames":["Biological: VAXCHORA (Cholera Vaccine, Live, Oral)"]},{"label":"Cohort 1 (placebo, 12 - 17 yrs)","type":"PLACEBO_COMPARATOR","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.","interventionNames":["Other: Placebo"]},{"label":"Cohort 2 (active, 6 - 11 yrs)","type":"EXPERIMENTAL","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.","interventionNames":["Biological: VAXCHORA (Cholera Vaccine, Live, Oral)"]},{"label":"Cohort 2 (placebo, 6 - 11 yrs)","type":"PLACEBO_COMPARATOR","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.","interventionNames":["Other: Placebo"]},{"label":"Cohort 3 (active, 2 - 5 yrs)","type":"EXPERIMENTAL","description":"Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.","interventionNames":["Biological: VAXCHORA (Cholera Vaccine, Live, Oral)"]},{"label":"Cohort 3 (placebo, 2 - 5 yrs)","type":"PLACEBO_COMPARATOR","description":"Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.","interventionNames":["Other: Placebo"]},{"label":"Historical Control: Adult Bridging Population","type":"OTHER","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118","interventionNames":["Biological: VAXCHORA (Cholera Vaccine, Live, Oral)"]}],"interventions":[{"type":"BIOLOGICAL","name":"VAXCHORA (Cholera Vaccine, Live, Oral)","description":"VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.","armGroupLabels":["Cohort 1 (active, 12-17 yrs)","Cohort 2 (active, 6 - 11 yrs)","Cohort 3 (active, 2 - 5 yrs)","Historical Control: Adult Bridging Population"]},{"type":"OTHER","name":"Placebo","description":"Placebo control for this study is normal (0.9%) saline.","armGroupLabels":["Cohort 1 (placebo, 12 - 17 yrs)","Cohort 2 (placebo, 6 - 11 yrs)","Cohort 3 (placebo, 2 - 5 yrs)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Cohort 1 (12-17 Yrs) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae","description":"The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer","timeFrame":"Day 11"},{"measure":"Cohort 2 (6 to <12 Years) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae","description":"The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer.","timeFrame":"Day 11"},{"measure":"Cohort 3 (2 to <6 Years) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae","description":"The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer.","timeFrame":"Day 11"},{"measure":"Cohort 1 (12-17 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years","description":"The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.","timeFrame":"Day 11"},{"measure":"Cohort 2 (6-11 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years","description":"The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.","timeFrame":"Day 11"},{"measure":"Cohort 3 (2-5 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years","description":"The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of18 and 45 years.","timeFrame":"Day 11"}],"secondaryOutcomes":[{"measure":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 29","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects","timeFrame":"Day 29"},{"measure":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 91","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 91 for all subjects","timeFrame":"Day 91"},{"measure":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 181","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 181 for all subjects","timeFrame":"Day 181"},{"measure":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 365","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 365 for all subjects","timeFrame":"Day 365"},{"measure":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 547","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 547 for all subjects","timeFrame":"Day 547"},{"measure":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 730","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 730 for all subjects","timeFrame":"Day 730"},{"measure":"Cohort 2 (6 to <12 Years) - Seroconversion of SVA - Day 29","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects","timeFrame":"Day 29"},{"measure":"Cohort 3 (2 to <6 Years) - Seroconversion of SVA - Day 29","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects","timeFrame":"Day 29"}],"otherOutcomes":[{"measure":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 1","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 1 for the subjects in the active treatment group and the placebo crossover group","timeFrame":"Day 1"},{"measure":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 91","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 91 for the subjects in the active treatment group and the placebo crossover group","timeFrame":"Day 91"},{"measure":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 181","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 181 for the subjects in the active treatment group and the placebo crossover group","timeFrame":"Day 181"},{"measure":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 365","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 365 for the subjects in the active treatment group who participate in the substudy.","timeFrame":"Day 365"},{"measure":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 547","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 547 for the subjects in the active treatment group who participate in the substudy.","timeFrame":"Day 547"},{"measure":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 730","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 730 for the subjects in the active treatment group who participate in the substudy.","timeFrame":"Day 730"},{"measure":"Safety - Solicited Adverse Events","description":"Evaluate the safety and tolerability of VAXCHORA by collecting solicited adverse events (abdominal pain, headache, lack of appetite, tiredness, diarrhea, nausea, vomiting and fever) by age cohort and overall through Day 8","timeFrame":"Through Day 8"},{"measure":"Safety - Unsolicited Adverse Events","description":"Evaluate the safety and tolerability of VAXCHORA by collecting unsolicited adverse events by age cohort and overall through Day 29","timeFrame":"Through Day 29"},{"measure":"Safety - Serious Adverse Events","description":"Evaluate the safety and tolerability of VAXCHORA by collecting serious adverse events by age cohort and overall through Day 181","timeFrame":"Through Day 181"},{"measure":"Acceptability","description":"Evaluate the acceptability of VAXCHORA using the percent of subjects in each age cohort able to complete the dosing according to protocol.","timeFrame":"Day 1"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or Female\n* Between 2 and \\<18 years of age on Day 1\n* In general good health\n* Able and willing to provide informed assent for study participation\n* Primary caregiver is able and willing to provide informed consent for study participation\n* (for females of childbearing potential) Using an acceptable method of contraception through Day 29\n\nExclusion Criteria:\n\n* Current acute gastrointestinal illness or loose stools within 3 days of Day 1 visit\n* Current acute febrile illness\n* History of cholera infection\n* History of cholera vaccination\n* History of severe allergic reaction (e.g. anaphylaxis) to any ingredient of VAXCHORA\n* Congenital or acquired immunodeficiency\n* Pregnancy (for females of childbearing potential)\n* Any other condition that, in the opinion of the Investigator, creates an unacceptable risk to the subject\n* Any other condition that, in the opinion of the Investigator, will interfere with the conduct of the study or the validity of the data\n* Duration of \\>2 weeks of abnormal stool pattern, defined as \\<3 stools per week or \\>2 stools per day in the past 6 months\n* Regular use of laxatives in the past 6 months\n* History of enterotoxigenic E. coli infection\n* Travel to cholera-endemic area in the previous 5 years\n* Nursing/Breastfeeding\n* Received or plans to receive the following from 14 days prior to the study vaccination through 11 days after vaccination: Any other licensed vaccines, antibiotics, or chloroquine\n* Received or plans to receive any other investigational agent throughout the main study (Day 181)","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Paul Andre de Lame, MD","affiliation":"Emergent BioSolutions","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Emory University","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Johnson County Clin-Trials, Inc.","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Heartland Research Associates, LLC","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"University of Kentucky","city":"Lexington","state":"Kentucky","zip":"40536","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Boston Medical Center","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"The Center for Pharmaceutical Research","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Rochester Clinical Research, Inc.","city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Aventiv Research Inc.","city":"Columbus","state":"Ohio","zip":"43123","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Coastal Carolina Research Center","city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"facility":"Clinical Research Associates, Inc.","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}}]},"referencesModule":{"references":[{"pmid":"31769402","type":"DERIVED","citation":"McCarty JM, Gierman EC, Bedell L, Lock MD, Bennett S. Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years. Am J Trop Med Hyg. 2020 Jan;102(1):48-57. doi: 10.4269/ajtmh.19-0241."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"This study included healthy volunteers (2 - 17 years) who were not previously immunized against cholera. A total of 574 subjects were screened, of which 24 were screen failures. A total of 550 subjects randomized, of which 471 received study treatment and 506 and 62 completed the main and sub studies, respectively. Recruitment July 2017-July 2018.\n\nThe historical control subjects are not included in the protocol enrollment number for PXVX-VC-200-006. They are solely a comparator population.","recruitmentDetails":"This study included healthy volunteers (2 - 17 years) who were not previously immunized against cholera. A total of 574 subjects were screened, of which 24 were screen failures. A total of 550 subjects randomized, of which 471 received study treatment and 433 and 73 completed the main study for treatment and placebo, respectively. Recruitment July 2017-July 2018.","groups":[{"id":"FG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"FG001","title":"Cohort 1 (Placebo, 12 - 17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline."},{"id":"FG002","title":"Cohort 2 (Active, 6 - 11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"FG003","title":"Cohort 2 (Placebo, 6 - 11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline."},{"id":"FG004","title":"Cohort 3 (Active, 2 - 5 Yrs)","description":"Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"FG005","title":"Cohort 3 (Placebo, 2 - 5 Yrs)","description":"Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline."},{"id":"FG006","title":"Historical Control: Adult Bridging Population","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118"}],"periods":[{"title":"Main Study (Day 1 - 181)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"163"},{"groupId":"FG001","numSubjects":"26"},{"groupId":"FG002","numSubjects":"158"},{"groupId":"FG003","numSubjects":"27"},{"groupId":"FG004","numSubjects":"150"},{"groupId":"FG005","numSubjects":"26"},{"groupId":"FG006","numSubjects":"2688"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"157"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"146"},{"groupId":"FG003","numSubjects":"24"},{"groupId":"FG004","numSubjects":"130"},{"groupId":"FG005","numSubjects":"25"},{"groupId":"FG006","numSubjects":"2687"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"20"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}]},{"type":"Failed Exl 8 and randomized in error","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}]},{"title":"Placebo Crossover (Day 181-365)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Only placebo subjects who opted to receive Vaxchora were included in the crossover group.","numSubjects":"13"},{"groupId":"FG001","comment":"Placebo subjects from Main study opted to cross over to the active group to receive Vaxchora.","numSubjects":"0"},{"groupId":"FG002","comment":"Only placebo subjects who opted to receive Vaxchora were included in the crossover group.","numSubjects":"11"},{"groupId":"FG003","comment":"Placebo subjects from Main study opted to cross over to the active group to receive Vaxchora","numSubjects":"0"},{"groupId":"FG004","comment":"Only placebo subjects who opted to receive Vaxchora were included in the crossover group.","numSubjects":"7"},{"groupId":"FG005","comment":"Placebo subjects from Main study opted to cross over to the active group to receive Vaxchora","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}]},{"title":"Long-term Follow-up (Day 365-730)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Cohort 1 subjects from the main study had to opt to be included in the Long-term follow-up study.","numSubjects":"73"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","comment":"Cohort 2 subjects were not eligible for the Long-term follow-up study.","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","comment":"Cohort 3 subjects were not eligible for the Long-term follow-up study.","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Subject did not want lab drawn","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"BG001","title":"Cohort 1 (Placebo, 12 - 17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline."},{"id":"BG002","title":"Cohort 2 (Active, 6 - 11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"BG003","title":"Cohort 2 (Placebo, 6 - 11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline."},{"id":"BG004","title":"Cohort 3 (Active, 2 - 5 Yrs)","description":"Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"BG005","title":"Cohort 3 (Placebo, 2 - 5 Yrs)","description":"Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline."},{"id":"BG006","title":"Historical Control: Adult Bridging Population","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586, PubMed ID: 29317118"},{"id":"BG007","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"163"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"158"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"150"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"2688"},{"groupId":"BG007","value":"3238"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"163"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"158"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"150"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"550"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2688"},{"groupId":"BG007","value":"2688"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14.4","spread":"1.7"},{"groupId":"BG001","value":"14.3","spread":"1.7"},{"groupId":"BG002","value":"8.6","spread":"1.8"},{"groupId":"BG003","value":"8.7","spread":"1.5"},{"groupId":"BG004","value":"3.5","spread":"1.1"},{"groupId":"BG005","value":"3.6","spread":"1.2"},{"groupId":"BG006","value":"30.0","spread":"7.8"},{"groupId":"BG007","value":"9.0","spread":"4.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"81"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"69"},{"groupId":"BG005","value":"17"},{"groupId":"BG006","value":"1482"},{"groupId":"BG007","value":"1746"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"77"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"81"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"1206"},{"groupId":"BG007","value":"1492"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"14"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"56"},{"groupId":"BG007","value":"61"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"8"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"53"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"67"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"671"},{"groupId":"BG007","value":"842"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"121"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"86"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"71"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"1855"},{"groupId":"BG007","value":"2184"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"50"},{"groupId":"BG007","value":"92"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"37"},{"groupId":"BG007","value":"37"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"163"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"158"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"150"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"2341"},{"groupId":"BG007","value":"2891"}]}]},{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"347"},{"groupId":"BG007","value":"347"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Cohort 1 (12-17 Yrs) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae","description":"The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"98.3% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 11","groups":[{"id":"OG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Cohort 1 (Placebo, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","lowerLimit":"95.4","upperLimit":"99.9"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"14.3"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"This analysis was based on the lower confidence limit and did not entail a comparative group. The requirement was for the lower limit of the 98.3% CI be at least 70%. Multiplicity adjustment due to co-primary endpoints allotted alpha=0.017 to this endpoint resulting in a 98.3% confidence interval","paramType":"Proportion","paramValue":"0.985","ciPctValue":"98.3","ciNumSides":"ONE_SIDED","ciLowerLimit":"0.7"}]},{"type":"PRIMARY","title":"Cohort 2 (6 to <12 Years) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae","description":"The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer.","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"98.3% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 11","groups":[{"id":"OG000","title":"Cohort 2 (Active, 6 - 11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Cohort 2 (Placebo, 6-11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","lowerLimit":"92.5","upperLimit":"99.4"},{"groupId":"OG001","value":"4.2","lowerLimit":"0.7","upperLimit":"20.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"This analysis was based on the lower confidence limit and did not entail a comparative group. The requirement was for the lower limit of the 98.3% CI be at least 70%. Multiplicity adjustment due to coprimary endpoints allotted alpha=0.017 to this endpoint resulting in a 98.3% confidence interval.","paramType":"Proportion","paramValue":"0.985","ciPctValue":"98.3","ciNumSides":"ONE_SIDED","ciLowerLimit":"0.7"}]},{"type":"PRIMARY","title":"Cohort 3 (2 to <6 Years) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae","description":"The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer.","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"98.3% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 11","groups":[{"id":"OG000","title":"Cohort 3 (Active, 2 - 5 Yrs)","description":"Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Cohort 3 (Placebo, 2-5 Yrs)","description":"Subjects aged 2 - 5 were administered a 50 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","lowerLimit":"91.5","upperLimit":"99.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"This analysis was based on the lower confidence limit and did not entail a comparative group. The requirement was for the lower limit of the 98.3% CI be at least 70%. Multiplicity adjustment due to coprimary endpoints allotted alpha=0.017 to this endpoint resulting in a 98.3% confidence interval.","paramType":"Proportion","paramValue":"0.985","ciPctValue":"98.3","ciNumSides":"ONE_SIDED","ciLowerLimit":"0.7"}]},{"type":"PRIMARY","title":"Cohort 1 (12-17 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years","description":"The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"98.3% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 11","groups":[{"id":"OG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Historical Control: Adult Bridging Population","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"2687"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","lowerLimit":"95.4","upperLimit":"99.9"},{"groupId":"OG001","value":"93.5","lowerLimit":"92.3","upperLimit":"94.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority was determined using the Newcombe method of determining the difference between two independent binomial distributions. Multiple comparison adjustment for co-primary endpoints allotted alpha=0.033 to this comparison. The lower limit of the 96.7% CI needed to be greater than -10 percentage points to prove non-inferiority.","paramType":"Risk Difference (RD)","paramValue":"5.8","ciPctValue":"96.7","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.4","ciUpperLimit":"7.1","estimateComment":"Newcombe method of determining the difference between two independent binomial distributions"}]},{"type":"PRIMARY","title":"Cohort 2 (6-11 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years","description":"The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"98.3% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 11","groups":[{"id":"OG000","title":"Cohort 2 (Active, 6-11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Historical Control: Adult Bridging Population","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"2687"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","lowerLimit":"92.5","upperLimit":"99.4"},{"groupId":"OG001","value":"93.5","lowerLimit":"92.3","upperLimit":"94.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority was determined using the Newcombe method of determining the difference between two independent binomial distributions. Multiple comparison adjustment for co-primary endpoints allotted alpha=0.033 to this comparison. The lower limit of the 96.7% CI needed to be greater than -10 percentage points to prove non-inferiority.","paramType":"Risk Difference (RD)","paramValue":"4.3","ciPctValue":"96.7","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"6.2"}]},{"type":"PRIMARY","title":"Cohort 3 (2-5 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years","description":"The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of18 and 45 years.","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"98.3% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 11","groups":[{"id":"OG000","title":"Cohort 3 (Active, 2-5 Yrs)","description":"Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Historical Control: Adult Bridging Population","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"2687"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","lowerLimit":"91.5","upperLimit":"99.6"},{"groupId":"OG001","value":"93.5","lowerLimit":"92.3","upperLimit":"94.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority was determined using the Newcombe method of determining the difference between two independent binomial distributions. Multiple comparison adjustment for co-primary endpoints allotted alpha=0.033 to this comparison. The lower limit of the 96.7% CI needed to be greater than -10 percentage points to prove non-inferiority.","paramType":"Risk Difference (RD)","paramValue":"4.5","ciPctValue":"96.7","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.1","ciUpperLimit":"6.4"}]},{"type":"SECONDARY","title":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 29","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 29","groups":[{"id":"OG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Cohort 1 (Placebo, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"97.6","upperLimit":"100"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"14.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Fisher's exact test was used to compare Vaxchora vaccine to placebo on the percent of subjects who seroconverted. For Vaxchora vs placebo within each cohort at each Day on study timepoint, the p-value was the same (p\\<0.0001).","pValue":"<0.0001","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 91","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 91 for all subjects","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 91","groups":[{"id":"OG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Cohort 1 (Placebo, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.6","lowerLimit":"79.2","upperLimit":"90.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"14.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Fisher's exact test was used to compare Vaxchora vaccine to placebo on the percent of subjects who seroconverted. For Vaxchora vs placebo within each cohort at each Day on study timepoint, the p-value was the same (p\\<0.0001).","pValue":"<0.0001","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 181","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 181 for all subjects","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 181","groups":[{"id":"OG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Cohort 1 (Placebo, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","lowerLimit":"66.0","upperLimit":"79.9"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"15.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Fisher's exact test was used to compare Vaxchora vaccine to placebo on the percent of subjects who seroconverted. For Vaxchora vs placebo within each cohort at each Day on study timepoint, the p-value was the same (p\\<0.0001).","pValue":"<0.0001","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 365","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 365 for all subjects","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 365","groups":[{"id":"OG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","lowerLimit":"57.0","upperLimit":"78.2"}]}]}]},{"type":"SECONDARY","title":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 547","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 547 for all subjects","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 547","groups":[{"id":"OG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","lowerLimit":"61.5","upperLimit":"82.3"}]}]}]},{"type":"SECONDARY","title":"Cohort 1 (12 to <18 Years) - Seroconversion of SVA - Day 730","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 730 for all subjects","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 730","groups":[{"id":"OG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","lowerLimit":"52.1","upperLimit":"75.3"}]}]}]},{"type":"SECONDARY","title":"Cohort 2 (6 to <12 Years) - Seroconversion of SVA - Day 29","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 29","groups":[{"id":"OG000","title":"Cohort 2 (Active, 6 - 11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Cohort 2 (Placebo, 6-11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","lowerLimit":"89.9","upperLimit":"97.5"},{"groupId":"OG001","value":"4.3","lowerLimit":"0.8","upperLimit":"21.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Fisher's exact test was used to compare Vaxchora vaccine to placebo on the percent of subjects who seroconverted. For Vaxchora vs placebo within each cohort at each Day on study timepoint, the p-value was the same (p\\<0.0001).","pValue":"<0.0001","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Cohort 3 (2 to <6 Years) - Seroconversion of SVA - Day 29","description":"Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 29","groups":[{"id":"OG000","title":"Cohort 3 (Active, 2 - 5 Yrs)","description":"Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Cohort 3 (Placebo, 2-5 Yrs)","description":"Subjects aged 2 - 5 were administered a 50 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","lowerLimit":"87.3","upperLimit":"97.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Fisher's exact test was used to compare Vaxchora vaccine to placebo on the percent of subjects who seroconverted. For Vaxchora vs placebo within each cohort at each Day on study timepoint, the p-value was the same (p\\<0.0001).","pValue":"<0.0001","statisticalMethod":"Fisher Exact"}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 1","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 1 for the subjects in the active treatment group and the placebo crossover group","reportingStatus":"NOT_POSTED","timeFrame":"Day 1","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 91","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 91 for the subjects in the active treatment group and the placebo crossover group","reportingStatus":"NOT_POSTED","timeFrame":"Day 91","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 181","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 181 for the subjects in the active treatment group and the placebo crossover group","reportingStatus":"NOT_POSTED","timeFrame":"Day 181","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 365","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 365 for the subjects in the active treatment group who participate in the substudy.","reportingStatus":"NOT_POSTED","timeFrame":"Day 365","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 547","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 547 for the subjects in the active treatment group who participate in the substudy.","reportingStatus":"NOT_POSTED","timeFrame":"Day 547","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Cohort 1 (12 to <18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 730","description":"Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 730 for the subjects in the active treatment group who participate in the substudy.","reportingStatus":"NOT_POSTED","timeFrame":"Day 730","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Safety - Solicited Adverse Events","description":"Evaluate the safety and tolerability of VAXCHORA by collecting solicited adverse events (abdominal pain, headache, lack of appetite, tiredness, diarrhea, nausea, vomiting and fever) by age cohort and overall through Day 8","reportingStatus":"NOT_POSTED","timeFrame":"Through Day 8","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Safety - Unsolicited Adverse Events","description":"Evaluate the safety and tolerability of VAXCHORA by collecting unsolicited adverse events by age cohort and overall through Day 29","reportingStatus":"NOT_POSTED","timeFrame":"Through Day 29","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Safety - Serious Adverse Events","description":"Evaluate the safety and tolerability of VAXCHORA by collecting serious adverse events by age cohort and overall through Day 181","reportingStatus":"NOT_POSTED","timeFrame":"Through Day 181","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Acceptability","description":"Evaluate the acceptability of VAXCHORA using the percent of subjects in each age cohort able to complete the dosing according to protocol.","populationDescription":"The data presented is for the population that was randomized and received treatment. For Cohort 2, 2 Vaxchora subjects and 1 placebo subject were randomized, but not treated. For Cohort 3, 4 Vaxchora subjects were randomized, but not treated.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percent of participants","timeFrame":"Day 1","groups":[{"id":"OG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG001","title":"Cohort 1 (Placebo, 12 - 17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline."},{"id":"OG002","title":"Cohort 2 (Active, 6 - 11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG003","title":"Cohort 2 (Placebo, 6 - 11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline."},{"id":"OG004","title":"Cohort 3 (Active, 2 - 5 Yrs)","description":"Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR."},{"id":"OG005","title":"Cohort 3 (Placebo, 2 - 5 Yrs)","description":"Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"156"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"146"},{"groupId":"OG005","value":"26"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"91.0"},{"groupId":"OG003","value":"96.2"},{"groupId":"OG004","value":"79.5"},{"groupId":"OG005","value":"73.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"All adverse events were collected for 28 days post vaccination. Serious adverse events were followed until the end of the end of the subject's participation in the study (2 years for adolescents in the long term sub-study and 6 months for all others). Solicited adverse events were collected for daily for 8 consecutive days following vaccination (Days 1-8). Events that continued past Day 8 were recorded as unsolicited adverse events.","description":"The Historical Control population is not included in this section as comparisons between the pediatric and adult populations were not specified to be conducted in the protocol.\n\nThe data below is not for randomized subjects, but for those included in the safety population.\n\nFor cohort 1, 2 subjects received Vaxchora instead of placebo; the subject count is 165 Vaxchora : 24 placebo.\n\nFor cohort 2, 1 subject received Vaxchora instead of placebo; the subject count is 157 Vaxchora : 25 placebo.","eventGroups":[{"id":"EG000","title":"Cohort 1 (Active, 12-17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.","deathsNumAffected":0,"deathsNumAtRisk":165,"seriousNumAffected":4,"seriousNumAtRisk":165,"otherNumAffected":116,"otherNumAtRisk":165},{"id":"EG001","title":"Cohort 1 (Placebo, 12 - 17 Yrs)","description":"Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline.","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":0,"seriousNumAtRisk":24,"otherNumAffected":13,"otherNumAtRisk":24},{"id":"EG002","title":"Cohort 2 (Active, 6 - 11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.","deathsNumAffected":0,"deathsNumAtRisk":157,"seriousNumAffected":0,"seriousNumAtRisk":157,"otherNumAffected":93,"otherNumAtRisk":157},{"id":"EG003","title":"Cohort 2 (Placebo, 6 - 11 Yrs)","description":"Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline.","deathsNumAffected":0,"deathsNumAtRisk":25,"seriousNumAffected":0,"seriousNumAtRisk":25,"otherNumAffected":15,"otherNumAtRisk":25},{"id":"EG004","title":"Cohort 3 (Active, 2 - 5 Yrs)","description":"Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nVAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.","deathsNumAffected":0,"deathsNumAtRisk":146,"seriousNumAffected":0,"seriousNumAtRisk":146,"otherNumAffected":74,"otherNumAtRisk":146},{"id":"EG005","title":"Cohort 3 (Placebo, 2 - 5 Yrs)","description":"Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.\n\nPlacebo: Placebo control for this study is normal (0.9%) saline.","deathsNumAffected":0,"deathsNumAtRisk":26,"seriousNumAffected":1,"seriousNumAtRisk":26,"otherNumAffected":12,"otherNumAtRisk":26}],"seriousEvents":[{"term":"Lower Limb Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Intentional Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":26}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Local Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":26}]}],"otherEvents":[{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Solicited Day 1 - 8","stats":[{"groupId":"EG000","numEvents":130,"numAffected":62,"numAtRisk":165},{"groupId":"EG001","numEvents":10,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":83,"numAffected":43,"numAtRisk":157},{"groupId":"EG003","numEvents":15,"numAffected":6,"numAtRisk":25},{"groupId":"EG004","numEvents":53,"numAffected":25,"numAtRisk":146},{"groupId":"EG005","numEvents":7,"numAffected":4,"numAtRisk":26}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Solicited Day 1 - 8","stats":[{"groupId":"EG000","numEvents":191,"numAffected":74,"numAtRisk":165},{"groupId":"EG001","numEvents":18,"numAffected":11,"numAtRisk":24},{"groupId":"EG002","numEvents":77,"numAffected":41,"numAtRisk":157},{"groupId":"EG003","numEvents":11,"numAffected":6,"numAtRisk":25},{"groupId":"EG004","numEvents":18,"numAffected":13,"numAtRisk":146},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":26}]},{"term":"Lack of Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Solicited Day 1 - 8","stats":[{"groupId":"EG000","numEvents":112,"numAffected":48,"numAtRisk":165},{"groupId":"EG001","numEvents":8,"numAffected":3,"numAtRisk":24},{"groupId":"EG002","numEvents":47,"numAffected":24,"numAtRisk":157},{"groupId":"EG003","numEvents":11,"numAffected":5,"numAtRisk":25},{"groupId":"EG004","numEvents":63,"numAffected":28,"numAtRisk":146},{"groupId":"EG005","numEvents":8,"numAffected":3,"numAtRisk":26}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Solicited Day 1 - 8","stats":[{"groupId":"EG000","numEvents":170,"numAffected":67,"numAtRisk":165},{"groupId":"EG001","numEvents":30,"numAffected":9,"numAtRisk":24},{"groupId":"EG002","numEvents":123,"numAffected":55,"numAtRisk":157},{"groupId":"EG003","numEvents":17,"numAffected":8,"numAtRisk":25},{"groupId":"EG004","numEvents":108,"numAffected":45,"numAtRisk":146},{"groupId":"EG005","numEvents":13,"numAffected":6,"numAtRisk":26}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Solicited Day 1 - 8","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":165},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":146},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":26}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Solicited Day 1 - 8","stats":[{"groupId":"EG000","numEvents":69,"numAffected":37,"numAtRisk":165},{"groupId":"EG001","numEvents":16,"numAffected":6,"numAtRisk":24},{"groupId":"EG002","numEvents":37,"numAffected":22,"numAtRisk":157},{"groupId":"EG003","numEvents":11,"numAffected":4,"numAtRisk":25},{"groupId":"EG004","numEvents":14,"numAffected":10,"numAtRisk":146},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":26}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Solicited Day 1 - 8","stats":[{"groupId":"EG000","numEvents":14,"numAffected":9,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":12,"numAffected":7,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":146},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":26}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Solicited Day 1 - 8","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":157},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":146},{"groupId":"EG005","numEvents":3,"numAffected":1,"numAtRisk":26}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Lack of Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":26}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":165},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Joint Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Arthropod Bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":26}]},{"term":"Vessel Puncture site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Loose Stool","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":30,"numAffected":23,"numAtRisk":165},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":24},{"groupId":"EG002","numEvents":19,"numAffected":18,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":8,"numAffected":8,"numAtRisk":146},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":26}]},{"term":"Rectal Tenesmus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":146},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":26}]},{"term":"Furuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Otitis Media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Ear Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":146},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unsolicited Day 29","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":146},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":26}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"David Cassie, Scientist, Clinical Research","organization":"Emergent BioSolutions Canada Inc.","email":"dcassie@ebsi.com","phone":"204-275-4589"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-11-15","uploadDate":"2020-09-08T11:04","filename":"Prot_000.pdf","size":10098173},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2017-11-28","uploadDate":"2020-09-08T11:05","filename":"SAP_001.pdf","size":3872789}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2020-10-05","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002771","term":"Cholera"}],"ancestors":[{"id":"D014735","term":"Vibrio Infections"},{"id":"D016905","term":"Gram-Negative Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"C000613802","term":"Vaxchora"},{"id":"D022121","term":"Cholera Vaccines"}],"ancestors":[{"id":"D001428","term":"Bacterial Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}